BioCryst Pharmaceuticals Inc Total Assets
BioCryst Pharmaceuticals Inc total assets. Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) holds total assets worth $465.05 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BCRX company net worth for the company's overall valuation and market capitalisation.
Total Assets of BioCryst Pharmaceuticals Inc (1994–2025)
Total assets of BioCryst Pharmaceuticals Inc from 1994 to 2025. This chart illustrates how BioCryst Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See BioCryst Pharmaceuticals Inc share price for real-time trading data and today's change.
BioCryst Pharmaceuticals Inc - Asset Composition Analysis
BioCryst Pharmaceuticals Inc Total Assets Breakdown (December 2025)
BioCryst Pharmaceuticals Inc total assets breakdown as of December 2025. BioCryst Pharmaceuticals Inc's total assets of $465.05 Million consist of 78.6% current assets and 21.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.5% |
| Accounts Receivable | $106.82 Million | 20.8% |
| Inventory | $5.40 Million | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is BioCryst Pharmaceuticals Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioCryst Pharmaceuticals Inc's current assets represent 78.6% of total assets in 2025, a decrease from 86.7% in 1994.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2025, down from 21.1% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 20.8% of total assets.
BioCryst Pharmaceuticals Inc Competitors by Total Assets
Key competitors of BioCryst Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
BioCryst Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 2.93 | 2.30 |
| Quick Ratio | 1.88 | 2.88 | 2.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $178.23 Million | $270.12 Million | $150.20 Million |
BioCryst Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between BioCryst Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 56.59 |
| Latest Market Cap to Assets Ratio | 4.19 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | $514.16 Million |
| Market Capitalization | $2.15 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BioCryst Pharmaceuticals Inc's assets at a significant premium (4.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BioCryst Pharmaceuticals Inc's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual total assets of BioCryst Pharmaceuticals Inc from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $514.16 Million | +4.84% |
| 2024-12-31 | $490.42 Million | -5.13% |
| 2023-12-31 | $516.96 Million | -6.01% |
| 2022-12-31 | $550.00 Million | -6.49% |
| 2021-12-31 | $588.15 Million | +75.72% |
| 2020-12-31 | $334.71 Million | +90.96% |
| 2019-12-31 | $175.28 Million | +19.37% |
| 2018-12-31 | $146.84 Million | -17.62% |
| 2017-12-31 | $178.26 Million | +98.40% |
| 2016-12-31 | $89.85 Million | -27.87% |
| 2015-12-31 | $124.56 Million | -9.00% |
| 2014-12-31 | $136.87 Million | +180.10% |
| 2013-12-31 | $48.87 Million | -14.93% |
| 2012-12-31 | $57.44 Million | -30.13% |
| 2011-12-31 | $82.21 Million | -25.65% |
| 2010-12-31 | $110.57 Million | -22.24% |
| 2009-12-31 | $142.19 Million | +67.89% |
| 2008-12-31 | $84.69 Million | -40.66% |
| 2007-12-31 | $142.72 Million | +108.39% |
| 2006-12-31 | $68.49 Million | -31.00% |
| 2005-12-31 | $99.25 Million | +205.68% |
| 2004-12-31 | $32.47 Million | +7.88% |
| 2003-12-31 | $30.10 Million | -27.13% |
| 2002-12-31 | $41.30 Million | -30.11% |
| 2001-12-31 | $59.10 Million | -16.56% |
| 2000-12-31 | $70.83 Million | -3.51% |
| 1999-12-31 | $73.40 Million | +152.23% |
| 1998-12-31 | $29.10 Million | +9.81% |
| 1997-12-31 | $26.50 Million | -28.57% |
| 1996-12-31 | $37.10 Million | +183.21% |
| 1995-12-31 | $13.10 Million | +2.34% |
| 1994-12-31 | $12.80 Million | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more